Abstract
The HIV-1 envelope protein glycoprotein 41 (gp41) is crucial in the HIV-1 infection process, therefore gp41 has emerged as an attractive target for drug design against AIDS. During the past few decades, tremendous efforts have been made on developing inhibitors that can prevent the HIV-1 entry process via suppressing functional gp41. In this review, the development of HIV-1 fusion inhibitors targeting gp41 including peptide inhibitors, small molecule inhibitors, vaccines and neutralized antibodies will be discussed.
Keywords: gp41, HIV-1, HIV-1 fusion inhibitor, membrane fusion.
Current Medicinal Chemistry
Title:Development of HIV-1 Fusion Inhibitors Targeting gp41
Volume: 21 Issue: 17
Author(s): K. Lu, M.R. Asyifah, F. Shao and D. Zhang
Affiliation:
Keywords: gp41, HIV-1, HIV-1 fusion inhibitor, membrane fusion.
Abstract: The HIV-1 envelope protein glycoprotein 41 (gp41) is crucial in the HIV-1 infection process, therefore gp41 has emerged as an attractive target for drug design against AIDS. During the past few decades, tremendous efforts have been made on developing inhibitors that can prevent the HIV-1 entry process via suppressing functional gp41. In this review, the development of HIV-1 fusion inhibitors targeting gp41 including peptide inhibitors, small molecule inhibitors, vaccines and neutralized antibodies will be discussed.
Export Options
About this article
Cite this article as:
Lu K., Asyifah M.R., Shao F. and Zhang D., Development of HIV-1 Fusion Inhibitors Targeting gp41, Current Medicinal Chemistry 2014; 21 (17) . https://dx.doi.org/10.2174/0929867321666131218094559
DOI https://dx.doi.org/10.2174/0929867321666131218094559 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erythropoietic Porphyrias: Animal Models and Update in Gene-Based Therapies
Current Gene Therapy Group VI Phospholipases A2: Homeostatic Phospholipases with Significant Potential as Targets for Novel Therapeutics
Current Drug Targets Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Attacking HIV Provirus: Therapeutic Strategies to Disrupt Persistent Infection
Infectious Disorders - Drug Targets Patented Aptamers for C-Reactive Protein Detection: A Review About their Use in Clinical Diagnostics
Recent Patents on DNA & Gene Sequences Regulatory Mechanisms of Calcineurin Phosphatase Activity
Current Medicinal Chemistry Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Mitochondria in Chronic Liver Disease
Current Drug Targets HIV-2 Infection and Chemokine Receptors Usage - Clues to Reduced Virulence of HIV-2
Current HIV Research Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design RETRACTED: Novel and safer self-inactivating vectors for gene therapy of Wiskott-Aldrich Syndrome
Current Gene Therapy The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development
Current Pharmaceutical Design In-Silico Algorithms for the Screening of Possible microRNA Binding Sites and Their Interactions
Current Genomics The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Regulation of the Metabolism of Polyunsaturated Fatty Acids and Butyrate in Colon Cancer Cells
Current Pharmaceutical Biotechnology Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology The Neuropeptide Galanin Benefits Insulin Sensitivity in Subjects with Type 2 Diabetes
Current Protein & Peptide Science IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued)